$1.67-0.05 (-2.63%)
InflaRx N.V., a clinical-stage biopharmaceutical company, discovers and develops inhibitors using C5a technology in Germany and the United States.
InflaRx N.V. in the Healthcare sector is trading at $1.67. Wall Street consensus targets $7.87 (7 analysts), implying a +372.5% move over the next 12 months. The stock is currently 44% below its 52-week high of $2.95, remaining 26.1% above its 200-day moving average. On fundamentals, Piotroski 1/9 flags weak fundamentals, Altman Z in the distress zone. Risk note: RSI 26 is oversold, raising the odds of a near-term bounce. The Whystock Score of 80/100 reflects bullish alignment across trend, valuation and analyst targets.
Simplified model based on P/E and ROE. Not a substitute for full valuation analysis. Data may be delayed. See our Terms.
InflaRx N.V., a clinical-stage biopharmaceutical company, discovers and develops inhibitors using C5a technology in Germany and the United States. The company's C5a is an inflammatory mediator to treat variety of autoimmune and other inflammatory dis...
InflaRx N.V. (NASDAQ:IFRX) is one of the 10 Most Volatile Penny Stocks to Buy Now. On May 13, 2026, Raymond James upgraded InflaRx N.V. (NASDAQ:IFRX) to Strong Buy from Outperform with a price target of $9, up from $7. Raymond James said sentiment is increasingly supported by a constructive view of InflaRx’s izicopan program in […]
InflaRx (NASDAQ:IFRX) outlined plans to prioritize development of izicopan, an oral inhibitor of the C5a receptor (C5aR), in ANCA-associated vasculitis (AAV) and other renal diseases during a company conference call led by CEO and founder Niels Riedemann. Izicopan positioned as a next-generation C5
InflaRx N.V. (NASDAQ:IFRX) is one of the top 10 hot penny stocks to buy now. InflaRx N.V. (NASDAQ:IFRX) announced on April 28 that it received a written notice from the Listing Qualifications Department of The Nasdaq Stock Market LLC on April 27, informing management that the company regained compliance with Nasdaq’s minimum bid price requirement […]
The United States market has shown robust performance, rising 3.4% over the last week and 35% over the past year, with earnings projected to grow by 16% annually. In such a thriving market, identifying stocks with strong potential for growth often involves looking beyond well-known names to those that might not be on every investor's radar. Penny stocks, though an older term, remain relevant as they often represent smaller or newer companies that could offer surprising value and stability...
By Karen Roman Exec Edge sat down with Nadeem Moiz, Chief Executive Officer at Revance, to learn more about the company’s vision in aesthetics, skincare and therapeutics. Exec Edge: Tell us about Revance and the science-powered products within your portfolio across aesthetics, skincare and therapeutics. At Revance we believe that science based innovative products drive […]